Hepatitis C virus (HCV) infection is estimated
|
|
- Esmond Watson
- 5 years ago
- Views:
Transcription
1 Interleukin-28B Genetic Variants and Hepatitis Virus Infection by Different Viral Genotypes Marco Antonio Montes-Cano, 1 José Raúl García-Lozano, 1 Cristina Abad-Molina, 1 Manuel Romero-Gómez, 2 Natalia Barroso, 3 José Aguilar-Reina, 3 Antonio Núñez-Roldán, 1 and María Francisca González-Escribano 1 Genetic host factors may modify the course of the hepatitis C virus (HCV) infection. Very recently, a genome-wide scan that reported association of the IL28B locus with response to treatment in HCV infection was published. The aim of the current study was to investigate the relationship of this locus with outcome of HCV infection in a cohort constituted by a total of 731 Spanish individuals. From these, 284 were subjects with persistent infection, 69 were individuals who naturally cleared the virus, and 378 were noninfected subjects. Genotyping of the rs (C>T) in the IL28B locus was performed using a TaqMan 5 0 allelic discrimination assay. The CC genotype was overrepresented among patients infected with viral genotypes non-1 (66.7% versus 39.1% in patients infected with viral genotype-1, P , odds ratio [OR] , 95% confidence interval [CI] ); patients with spontaneous resolution of infection (72.5% versus 45.6% of the individuals with persistent infection, P ,OR5 0.32; 95%CI, ); and lastly, patients with sustained response (60.2% versus 32.1% found in patients with nonsustained response, P ,OR5 0.31; 95%CI, ). Conclusion: We have found different rates of viral genotype infection depending on the IL28B variant as well as an association of this locus with natural and treatment-mediated response. (HEPATOLOGY 2010;52:33-37) Hepatitis C virus (HCV) infection is estimated to affect 170 million people worldwide. This infection results in a chronic active hepatitis in more than 80% of the infected patients, of which 20%-30% develop progressive fibrosis and cirrhosis, whereas only approximately 10%-20% of the infected people spontaneously eliminate the virus. 1 Different factors may influence the ability to spontaneously clear the virus. Ethnic differences in clearance frequency Abbreviations: CHC, chronic hepatitis C; CI, confidence interval; G1, viral genotype 1; HCV, hepatitis C virus; IFN-a interferon alpha; IL28B, interleukin-28b; NIS, noninfected subjects; NSR, nonsustained response; OR, odds ratio; RBV, ribavirin; SNP, single-nucleotide polymorphism. From the 1 Servicio de Inmunología, Hospital Universitario Virgen del Rocío/ Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain; 2 UCM de enfermedades digestivas y Ciberehd, Hospital Universitario de Valme, Universidad de Sevilla, Sevilla, Spain; and 3 Servicio de Digestivo Hospital Universitario Virgen del Rocío, Sevilla, Spain. Received November 26, 2009; accepted February 16, Supported by a grant from the FIS 07/0061 Fondos FEDER and Plan Andaluz de Investigación (PAI, grupos CTS-0197 and CTS-0102). Address reprint requests to: María Francisca González-Escribano, Servicio de Inmunología, Hospital Universitario Virgen del Rocío, Sevilla, Spain. mariaf.gonzalez.sspa@juntadeandalucia.es; fax: (34) Copyright VC 2010 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience ( DOI /hep Potential conflict of interest: Nothing to report. suggest involvement of host genetic variations in spontaneous viral clearance. 2 Currently, the most effective initial therapy for viral clearance is the combination of interferon-alpha (IFN-a) and rivabirin (RBV); however, this standard therapy does not produce sustained response in all the patients treated. Different factors have been evaluated as predictors of the sustained response to treatment, with controversial results. 3 Very recently, a genome-wide association study identified a single nucleotide polymorphism (SNP) rs (C>T) that was strongly associated with sustained virological response to the treatment with pegylated IFN-a and RBV in a cohort of more than 1600 American individuals (with different ethnicity) chronically infected with the genotype 1 of the HCV. 4 This SNP is located on chromosome 19q13, 3 kilobases (kb) upstream of the interleukin-28b (IL28B) gene that encodes a type III IFN (IFN-k3). Almost simultaneously with this first study, another two genome-wide association studies reporting an association of the response to IFN-a and RBV treatment with the IL28B locus (although with different SNPs) have been published in Australian and a Japanese patient cohorts. 5,6 An association of rs with natural viral clearance in six different cohorts of individuals with diverse 33
2 34 MONTES-CANO ET AL. HEPATOLOGY, July 2010 ethnic origins has also been reported. 7 The aim of this study was to explore the influence of the rs variations in the outcome of HCV infection in the Spanish population. Patients and Methods A total cohort consisting of 731 Spanish individuals were included in this study. They were selected by using surnames and by having grandparents born in Spain. This cohort included 284 subjects with persistent infection, 69 individuals who naturally cleared the virus, and 378 noninfected subjects. The persistent infection group included 166 males and 118 females suffering from biopsy-proven chronic hepatitis C (CHC) with compensated liver disease followed in the outpatient clinic of the Hospital Universitario Virgen del Rocío and Hospital Universitario de Valme (Sevilla, Spain) from 2001 to All CHC patients were hepatitis B surface antigen and human immune deficiency virus negative, anti-hcv positive, and HCV RNA positive in serum. Anti-HCV, HbsAg, and human immune deficiency virus were determined by commercially available methods (HCV 3.0 test, ORTHO, and Enzygnost hepatitis B surface antigen 5.0 and anti-human immune deficiency virus-1/2 plus; DADE, Behring, respectively). Percutaneous liver biopsies were performed under ultrasonographic control. A portion of the biopsy specimen was used for the histology diagnosis. Disease staging was defined according to Scheuer, 8 with ranking from F0 (absence of fibrosis) to F4 (cirrhosis stage). Patients were stratified into two groups: F0-F2, absence of fibrosis to moderate fibrosis; and group F3-F4, with advanced fibrosis-cirrhosis. Data of response to treatment (51.4% received IFN-a, and 48.6% IFN-a plus RVB) were available in 219 patients; 113 of them had a sustained response (SR), HCV RNA levels remained undetectable during 6 months after therapy discontinuation) and 106 had a nonsustained response (NSR), including nonresponder patients (HCV RNA levels detectable during the completed period of the treatment) and relapsed responder patients (undetectable HCV RNA during the therapy but detectable after discontinuation). The group with spontaneous viral clearance comprised 29 men and 40 women who were anti-hcv positive and HCV-RNA negative. Most of these subjects were blood donors with anti-hcv positive in the routine screening of viral antibodies; these subjects are referred to the hepatology unit and, according to the established protocol, HCV-RNA detection is performed. Lastly, a group of 223 male and 155 female blood and bone marrow donors (noninfected subjects [NIS]) were considered as representative of the normal frequencies of the SNP studied in the Spanish population. Patients and controls agreed to a blood examination according to the guidelines of the Hospital Bioethic Committee. Genotyping. DNA from patients and controls was extracted from peripheral blood using standard methods. Genotyping of the rs was performed using a TaqMan 5 0 allelic discrimination assay (Applied Biosystems, Foster City, CA). The primers used were 5 0 GCCTGTCGTGTACTGAACCA 3 0 (forward) and 5 0 GCGCGGAGTGCAATTCAAC 3 0 (reverse), and the TaqMan MGB probe sequences were 5 0 TGGTTCGCGCCTTC 3 0 and 5 0 CTGGTTCA CGCCTTC 3 0. The probes were labeled with the fluorescent dyes VIC and FAM, respectively. Polymerase chain reaction reactions were carried out in a total volume of 8 ll with the following amplification protocol: denaturation at 95 C for 10 minutes, followed by 40 cycles of denaturation at 92 C for 15 seconds, and finished with annealing and extension at 60 C for 1 minute. Genotyping of each sample was automatically attributed by the SDS 1.3 software for allelic discrimination. Statistical Analysis. Genotypic frequencies were obtained by direct counting, and statistical analysis was performed by the chi-squared test calculated on 2 2 contingency tables assuming a recessive model (CC versus CTþTT) using the Statcalc program (Epi Info version 6.0; Centers for Disease Control and Prevention, Atlanta, GA). Odds ratio (OR) with 95% confidence intervals (95% CI) was calculated using the same program. Median values of quantitative variables were compared using a nonparametric test (Mann- Whitney two-tailed test). P-values less than 0.05 were considered statistically significant. Results Genotypes of the rs were unequivocally assigned in all the cases, except in one of the individuals with persistent infection, who was eliminated from the analysis (CHC genotypes n ¼ 283), and they were in Hardy-Weinberg equilibrium in the NIS control group (CC: 44.7%, CT: 42.1%, and TT: 13.2%; C 0.66 and T 0.34). Demographic data, viral genotype and viral load, route of infection, fibrosis stage, and biochemical features of our CHC cohort are displayed in Table 1. With regard to the viral genotypes, 74.2% of the CHC patients were infected with viral genotype
3 HEPATOLOGY, Vol. 52, No. 1, 2010 MONTES-CANO ET AL. 35 Table 1. Demographic and Biochemical Features of Patients with Chronic Hepatitis C Included in This Study CHC CC (%) CT1TT (%) P OR (95%CI) Males (48.8) 85 (51.2) Females (41.0) 69 (59.0) 0.2 Viral genotype 1* (39.1) 128 (60.9) Viral genotype non (66.7) 22 (33.3) ( ) F0-F (46.5) 108 (53.5) F3-F (43.2) 46 (56.8) 0.69 Transfusion (46.6) 39 (53.4) Nontransfusion (46.8) 59 (53.2) Unknown (43.4) 56 (56.6) 0.86 Age of infection (years) ALT (IU/L) AST (IU/L) GGT (IU/L) Alkaline phosphatase (IU/L) Viral load (10 6 ) copies/ml Data of patients stratified according to their rs genotypes are also displayed. Qualitative variables are shown as number and percentage of individuals; quantitative variables are displayed as median. *Patients with HCV genotype coinfections were eliminated from this analysis (n ¼ 276). F0-F2, absence of fibrosis-moderate fibrosis; F3-F4, advanced fibrosiscirrhosis; OR, odds ratio; CI, confidence interval. 1 (G1), 23.3% were infected with non-1 viral genotype (non-g1) (4.2% with genotype 2, 15.2% with genotype 3, and 3.9% with genotype 4), and the rest (2.5%) had co-infections with different HCV genotypes. When patients were stratified according to their rs genotypes (CC versus CTþTT), the CC genotype was overrepresented among non-g1 (66.7%) on comparing with both G1-infected patients (39.1%, P ¼ ,OR¼ 0.32, 95%CI ¼ ) and NIS (44.7%, P ¼ 0.001, OR ¼ 0.40, 95%CI ¼ ), whereas frequency of the CC genotype among G1-infected patients was similar to that of the NIS group (P ¼ 0.18). Moreover, we found higher median levels of alanine aminotransferase (106.0 IU/L versus 85.5 IU/L, P ¼ 0.006) and lower median levels of gamma-glutamyltransferase (35.5 IU/L versus 41.0 IU/L, P ¼ 0.002) in patients CC when compared with patients CTþTT. No statistical significant differences between individuals CC and CTþTT were observed in any other cases (Table 1). Results obtained regarding the effect of the rs variations in the spontaneous HCV clearance in our study are displayed in Table 2. The CC genotype was associated with the spontaneous resolution of infection; 72.5% of those individuals who cleared the virus had the CC genotype versus 44.7% of the NIS group (P ¼ ,OR¼ 0.31, 95%CI ¼ ) and 45.6% of the CHC group (P ¼ ,OR¼ 0.32, 95%CI ¼ ), whereas individuals with persistent infection had a frequency of this genotype similar to that of the NIS group (CHC versus NIS, P ¼ 0.82). Next, we tested whether the effect of this polymorphism was the same in both sexes, because this factor had been the most consistently associated with natural elimination of the virus. The rs CC genotype was associated with spontaneous clearance in both men and women. Regarding viral clearance after treatment, data of response were available in 219 patients; those 65 subjects without data of response were excluded from this part of the study. Viral clearance after treatment was associated with the IL28B locus, because frequency of rs cc among patients with SR (n ¼ 113) was 60.2% versus 32.1% found in patients with NSR (n ¼ 106) (P ¼ ,OR¼ 0.31, 95%CI ¼ ). We found an association of this polymorphism with SR in the monotherapy as well as in the combined therapy groups. In the monotherapy group, frequency of CC patients with SR was 35 of 58 (60.3%) versus 20 of 54 (37.0%) among patients with NSR (P ¼ 0.01, OR ¼ 0.39, 95%CI ¼ ), and in the combined therapy group, frequency of CC patients with SR was 33 of 55 (60.0%) versus 14 of 52 (26.9%) among patients with NSR (P ¼ ,OR¼ 0.25, 95%CI ¼ ) (Table 3).Therefore, according to our data, distribution of rs genotypes relating to the response was the same in both treatment schedules, and consequently, we combined both therapy groups for analysis. Finally, when patients were stratified by their viral genotypes, the rate of SR in CC patients infected by non-g1 was 87.2% (34/39) and 84.2% in CTþTT patients infected by non-g1 (16/19, P ¼ 0.76); whereas in patients CC infected with G1 was 53.9% (34/63) and in patients CTþTT infected with G1 was 29.6% (29/98, P ¼ ,OR¼ 0.36, 95%CI ¼ ).
4 36 MONTES-CANO ET AL. HEPATOLOGY, July 2010 Table 2. Effect of the rs SNP on Spontaneous Clearance of the HCV in the Spanish Population Discussion CC (%) CT1TT (%) Spontaneous viral clearance*, 50 (72.5) 19 (27.5) Chronic hepatitis C 129 (45.6) 154 (54.4) Noninfected subjects 169 (44.7) 209 (55.3) Spontaneous viral clearance males 21 (72.4) 8 (27.6) Spontaneous viral clearance females 29 (72.5) 11 (27.5) Data of distribution of rs genotypes in males and females with spontaneous viral clearance are also displayed. *Comparison spontaneous viral clearance versus chronic hepatitis; P ¼ ;OR¼ 0.32; 95% CI, Comparison spontaneous viral clearance versus noninfected subjects; P ¼ ;OR¼ 0.31; 95%CI, Comparison spontaneous viral clearance males versus females; P ¼ 1.0. In this study, we found a preference of the HCV genotypes to infect individuals with a determinate rs genotype and association of the IL28B locus with spontaneous viral clearance as well as with the response to treatment in the Spanish population. Very recently, three genome-wide association studies have reported an association between the IL28B locus and the response to IFN-a and RBV therapy in HCVinfected patients. 4-6 In our study, the rs cc genotype was overrepresented in SR patients. The association was detected in both patients treated with only IFN-a and patients treated with the combined therapy IFN-a and RBV. The group of patients bearing the genotype associated with a better response had lower pretreatment median levels of gamma glutamyltransferase, which is the aminotransferase more consistently associated with the SR, with OR comparable to viral genotype Levels of alanine aminotransferase were higher in our group of CC patients with CHC; although this aminotransferase has not been clearly associated with SR, some authors described association of higher levels in the baseline with SR in patients infected with non- G1. 12 Except for frequency of the viral genotypes, we did not find differences between both rs genotype groups and the rest of the factors analyzed previously described as related to SR. All three previous studies support a robust association of the IL28B locus with the response to the antiviral therapy across different population groups, including only viral genotype 1- infected patients. This is the most common viral genotype in developed countries and the poorest responder to therapy (40%-50% of responder versus 75% of patients infected with others genotypes). The current study included 23.3% of non-g1-infected patients, and, surprisingly, determinate HCV genotypes had preference by individuals with a particular rs genotype because the frequency of subjects bearing CC was overrepresented among non-g1-infected patients (66.7%). Although these results need confirmation in other cohorts, taking into account frequency of rs CC genotype in our noninfected population (44.7%), we could speculate with a possible positive selection of individuals rs CC by the non-g1 virus or, conversely, a negative selection of these subjects by the G1 (39.1%). In this sense, both the highest rs C allelic frequency and the greatest rate of infection by non-g1 viral HCV genotypes have been described in Asian populations, whereas the lowest frequency of C allele and the highest rates of G1 infection have been described in African populations. 4,13 Some studies support the idea that elements of both innate and adaptive immune response could be under selective pressure in viral infections, and this fact could determine the final picture found in observational studies There exists no systematic explanation for the viral genotype-specific differences found in response to treatment; therefore, if non-g1 viral genotypes had a preference to infect patients with a determinate IL28B genotype, influence currently attributed to the virus could be caused, at least partially, by the host genetic background. Although the individuals included in some combinations of viral and Table 3. Effect of the rs SNP on Clearance After Treatment in the Spanish HCV-Infected Patients CC (%) CT1TT (%) P OR 95%CI IFNa Monotherapy Group Sustained response 35 (60.3) 23 (39.7) Nonsustained response 20 (37.0) 34 (63.0) ( ) IFNa þ RBV Combined Therapy Group Sustained response 33 (60.0) 22 (40.0) Nonsustained response 14 (26.9) 38 (73.1) ( ) Combined Group Sustained response 68 (60.2) 45 (39.8) Nonsustained response 34 (32.1) 72 (67.9) ( ) Data of distribution of rs genotypes in patients with different treatment schedules are also displayed. OR, Odds ratio; CI, confidence interval.
5 HEPATOLOGY, Vol. 52, No. 1, 2010 MONTES-CANO ET AL. 37 host genotypes did not permit statistical analysis, our results suggest an influence of both host and virus factors in the SR. In this sense, the highest rate of SR was found in CC patients infected by non-g1 (87.2%) and the lowest among individuals CTþTT infected with G1 (29.6%). The influence of the host genotype could be stronger among individuals infected by G1 (rate of response of CC 53.9% versus 29.6% in CTþTT) than among those infected by non-g1 (rate of response of CC 87.2% versus 84.2% in CTþTT). Further studies are needed to clarify the weight of these factors in the response. Another question is whether this gene is involved in natural viral clearance. During the preparation of this manuscript, a paper describing an association of this SNP with natural viral clearance in six different cohorts of individuals with different ethnic origins was published. 7 This study reported association of this polymorphism with natural viral clearance among American individuals with both European and African ancestry. The current study shows a similar association between rs and natural viral clearance, because frequency of the CC genotype was overrepresented in individuals with spontaneous viral clearance. Therefore, our results support the same conclusion as the previous study in a Spanish cohort. This association seems to be independent of sex, which is a factor consistently associated with natural clearance. In conclusion, we have found different rates of viral genotype infection depending on IL28B variant as well as an association of this locus with natural and treatment-mediated response. References 1. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9: Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-d immunoglobulin: Irish Hepatology Research Group. N Engl J Med 1999;340: Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008;49: Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;46: Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat Genet 2009;41: Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41: Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461: Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13: Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130: Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, el al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. HEPATOLOGY 2003;37: von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129: Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357: Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009;24: Pang PS, Planet PJ, Glenn JS. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One 2009;11:e Telenti A. Adaptation, co-evolution, and human susceptibility to HIV- 1 infection. Infect Genet Evol 2005;5: Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009;458:
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationDetection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection
Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus (HBV) infection Asterios Saitis 1, Nikolaos K. Gatselis 1, Kalliopi Azariadi
More informationGenetic Determinants in HCV
Genetic Determinants in HCV Lynn E. Taylor, MD Assistant Professor of Medicine Warren Alpert Medical School of Brown University The Miriam Hospital Providence, RI April 27, 2011 Disclosure My presentation
More informationThe time factor in the management of chronic hepatitis C
11-8/8//4/2-235 REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS Copyright 8 ARÁN EDICIONES, S. L. REV ESP ENFERM DIG (Madrid) Vol.. N. 4, pp. 2-235, 8 POINT OF VIEW The time factor in the management of chronic
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationCriteria Grid Hepatitis C Research Studies, Tools, and Surveillance Systems. Part A. Basic Science Clinical Science Public Health/Epidemiology
Criteria Grid Hepatitis C Research Studies, Tools, and Surveillance Systems Best Practice/Intervention: Date of Review: March 23, 2015 Reviewer(s): Christine Hu Category: Shi KQ. et al. (2012) Interleukin-28B
More informationMedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article
DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationA meta-analysis of the association between IL28B polymorphisms and infection susceptibility of hepatitis B virus in Asian population
Chen et al. BMC Gastroenterology (2015) 15:58 DOI 10.1186/s12876-015-0286-2 RESEARCH ARTICLE Open Access A meta-analysis of the association between IL28B polymorphisms and infection susceptibility of hepatitis
More informationIL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population
876 Martínez-Gómez LE, et al., 2012; 11 (6): 876-881 ORIGINAL ARTICLE November-December, Vol. 11 No.6, 2012: 876-881 IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment
More informationSupplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC
Supplementary Table 1. The distribution of IFNL rs12979860 and rs8099917 and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC rs12979860 (n=3129) CC 1127 1145.8 CT 1533 1495.3 TT
More informationHepatitis C Virus. https://www.labcorp.com/wps/wcm/connect/labcorp+content/labcorp/education+and+re...
Page 1 of 16 Hepatitis C Virus Data reflected in this report are based solely on the collection of samples submitted to LabCorp for testing. Refer to the limitations section of this report for additional
More informationASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING?
ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING? DO WE NEED LIVER BIOPSY? Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA POTENTIAL
More informationPharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV co-infected patients
1 Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV co-infected patients Evaldo Stanislau Affonso de Araújo 1*&, Harel Dahari 2*$, Scott J Cotler 2, Thomas
More informationJPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print. Durability of Response in Children Treated with Pegylated Interferon
JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print DOI : 10.1097/MPG.0000000000000929 Durability of Response in Children Treated with Pegylated Interferon alfa-2a +/- Ribavirin
More informationInterferon Lambda-3 rs Variants and Response to Pegylated Interferon in Chronic Hepatitis-C Genotype-3
ORIGINAL ARTICLE Interferon Lambda-3 rs12979860 Variants and Response to Pegylated Interferon in Chronic Hepatitis-C Genotype-3 ABSTRACT Objective: To assess the role of single nucleotide polymorphisms
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationThe treatment of choice for chronic hepatitis C is
Early Identification of HCV Genotype 1 Patients Responding to 24 Weeks Peginterferon -2a (40 kd)/ribavirin Therapy Donald M. Jensen, 1 Timothy R. Morgan, 2 Patrick Marcellin, 3 Paul J. Pockros, 4 K. Rajender
More informationPegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.08 Subsection: Anti-infective Agents Original Policy Date: January 1, 2006 Subject: Pegasys Ribavirin
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationCLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT
GASTROENTEROLOGY 2010;138:2307 2314 Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin JEANETTE J. MCCARTHY,* JOSEPHINE H. LI,* ALEXANDER
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationReduced telaprevir dosing in combination therapy for patients with chronic hepatitis C
Original Contribution Kitasato Med J 2017; 47: 1-9 Reduced telaprevir dosing in combination therapy for patients with chronic hepatitis C Wataru Ando, 1 Yumi Fukunaga, 1 Hiroaki Yokomori, 2 Takako Komiyama
More informationOptimal ltherapy in non 1 genotypes:
Optimal ltherapy in non 1 genotypes: genotype 2 and 3 patients Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy craxanto@unipa.it Peg IFN alpha plus ribavirin : SVR rate of >80%
More informationROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV
ROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV (Especially HCV-6) WK Seto Clinical Assistant Professor Department of Medicine Queen Mary Hospital The University of Hong Kong HCV GENOTYPES:
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More informationReview Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationUNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS PHARMACOGENETICS AND THE APPLICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationPrediction of Response to Pegylated Interferon plus Ribavirin by IL28B Gene Variation in Patients Coinfected with HIV and Hepatitis C Virus
MAJOR ARTICLE Prediction of Response to Pegylated Interferon plus Ribavirin by IL28B Gene Variation in Patients Coinfected with HIV and Hepatitis C Virus Juan A. Pineda, 1 Antonio Caruz, 3 Antonio Rivero,
More informationPredictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid
Predictors of Response to Hepatitis C Therapy in the DAA Era Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid Why Predicting HCV Response? Select candidates for therapy Prioritizing
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationIL10 rs polymorphism is associated with liver cirrhosis and chronic hepatitis B
IL10 rs1800896 polymorphism is associated with liver cirrhosis and chronic hepatitis B L.N. Cao 1, S.L. Cheng 2 and W. Liu 3 1 Kidney Disease Department of Internal Medicine, Xianyang Central Hospital,
More informationASIAN CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGYLATED-
IL28B GENOTYPE IS NOT USEFUL FOR PREDICTING TREATMENT OUTCOME IN ASIAN CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGYLATED- INTERFERON-α 1 Jacinta A Holmes 1 *, Tin Nguyen 1, Dilip Ratnam 2, Neel M Heerasing
More informationDisclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR
29/9/214 Genetic determinants of ᴧ HCV treatment outcome Disclosures Advisory board member - Gilead, Abbvie, Bristol-Myers Squibb (BMS), Janssen, Merck, and oche Speaker - Gilead, Janssen, Merck, BMS,
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationIntron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.06 Subject: Intron A Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Intron A Ribavirin Description
More informationEPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE
EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE E. Angeli, A. Mainini, C. Atzori, G. Gubertini and G. Rizzardini II Dept. Infectious
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationIntron A (interferon alfa-2b) with ribavirin, (Copegus, Moderiba, Rebetol, Ribapak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Ribavirin Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Ribavirin Description
More informationMEDIC CENTER. Case 2
Case 2 Case history 57 year old Vietnamese man He lives in HCM city and works as a engineer The patient presented in July 2012 with fatigue Diagnosed with HCV in 2004 Negative for both HBV and HIV antibodies
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Long-term Pegylated Interferon Monotherapy Following 72 Weeks of Pegylated Interferon and Ribavirin in Hepatitis C Virus Genotype-1-infected Slow Responders Shinya Watanabe 1, Yoshimasa
More informationHealthy Liver Cirrhosis
Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationThe Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (10), Page
The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (10), Page 7842-7849 Comparison between clinical and biochemical versus interleukin 28B as a predictive factor of virological response to
More informationInfergen (interferon alfacon-1) with Ribavirin (Copegus, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.04 Subject: Infergen with Ribavirin Page: 1 of 8 Last Review Date: March 13, 2014 Infergen with Ribavirin
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationTitle: Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment
Title: Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment Authors: Yolanda Sánchez-Torrijos, Jara Eloísa Ternero Vega, Carmen Cepeda Franco
More informationThe Predictors of Response of Treatment of HCV Patients by Interferon and Ribavirin
Med. J. Cairo Univ., Vol. 85, No. 4, June: 1491-1496, 2017 www.medicaljournalofcairouniversity.net The Predictors of Response of Treatment of HCV Patients by Interferon and Ribavirin NORAN A. EL-KORDY,
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationIL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin
IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin Norma I. Rallón a, Vincent Soriano a, Susanna Naggie b, Clara Restrepo
More informationHCV RNA profiles among chronic HIV/HCV coinfected individuals in ESPRIT; spontaneous HCV RNA clearance observed in 9 individuals
HCV RNA profiles among chronic HIV/HCV coinfected individuals in ESPRIT; spontaneous HCV RNA clearance observed in 9 individuals Daniel GRINT 1,2, Ellen TEDALDI 3, Lars PETERS 4, Amanda MOCROFT 1, Brian
More informationDeterminants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus
Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus Leah Burke, M.D. 1, Daniel Fierer, M.D. 2, David Cassagnol,
More informationARD Online First, published on September 8, 2005 as /ard
ARD Online First, published on September 8, 2005 as 10.1136/ard.2005.046094 Lack of association between ankylosing spondylitis and a functional polymorphism of PTPN22 proposed as a general susceptibility
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationOver the last 2 years exciting novel pharmacogenetic
Clinical Utility of Interleukin-28B Testing in Patients With Genotype 1 Michelle Lai and Nezam H. Afdhal See Editorial on Page 5 Over the last 2 years exciting novel pharmacogenetic data have emerged on
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationVicente Soriano Department of Infectious Diseases
Predictors of Response to Hepatitis C Therapy Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain Diagnosis Therapy IL28B alleles Non-invasive liver fibrosis methods Viral
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationRitsuzo Kozuka, Hoang Hai, Yuga Teranishi, Hiroyuki Motoyama, Etsushi Kawamura, Atsushi Hagihara, Sawako Uchida
Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy Ritsuzo Kozuka, Hoang Hai, Yuga
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationRESEARCH ARTICLE. Rattanaporn Kiatbumrung 1, Natthaya Chuaypen 1, Sunchai Payungporn 1, Anchalee Avihingsanon 2, Pisit Tangkijvanich 1 * Abstract
RESEARCH ARTICLE Editorial Process: Submission:01/19/2018 Acceptance:07/23/2018 The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection
More informationHepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011
Hepatitis C Update Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Outline n Educational Objectives Epidemiology and Natural History of Hepatitis C Current Treatment
More informationCASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be?
Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? CASE STUDY Pham Thi Thu Thuy MD, PhD Ho Chi Minh City Vietnam Serious Adverse
More informationWaseem Hamoudi MD*, Sami Al-Smadi MD*, Karim Lutfi MD*, Moath Azizi MD*, Yousef Niomat MD* ABSTRACT
Durability of Sustained Virological Response and Long Term Follow Up To Pegylated Interferon and Ribavirin in Treated Patients with Chronic Hepatitis C Waseem Hamoudi MD*, Sami Al-Smadi MD*, Karim Lutfi
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationAccepted Manuscript. S (16)30397-X Reference: JHEPAT To appear in: Journal of Hepatology
Accepted Manuscript High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis Helder Cardoso, Ana Maria Vale, Susana Rodrigues,
More informationDelta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne
Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne Delta hepatitis treatment in 2018 Currently, Peg-IFNα 180 µg/wk is the only effective treatment
More informationGenotype 4. Sanaa Kamal, M.D., Ph.D. Professor. Ain Shams University, Cairo, Egypt Tufts School of Medicine
Optimal Therapy in Hepatitis C Genotype 4 Sanaa Kamal, M.D., Ph.D. Professor Ain Shams University, Cairo, Egypt Tufts School of Medicine Boston; USA HCV Genotype 4 True or False HCV-G4 is limited to Africa
More informationNew Treatments for HCV: Perspective From Asia
REVIEW New Treatments for HCV: Perspective From Asia Ming-Lung Yu, M.D., Ph.D.,*, Wan-Long Chuang, M.D., Ph.D.*, Introduction The prevalence and number of people with antibodies to hepatitis C virus (anti-hcv)
More informationTHE IMPACT OF HLA CLASS I ON VIROLOGICAL OUTCOMES OF HBV
THE IMPACT OF HLA CLASS I ON VIROLOGICAL OUTCOMES OF HBV Philippa Matthews Consultant in Infectious Diseases & Microbiology SUPPRESSION CO-EVOLUTION ESCAPE Host factors associated with the clinical course
More informationThe medical management of hepatitis C
CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α-2a PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS INFECTED WITH HIV: THE APRICOT STUDY Douglas T. Dieterich, MD* ABSTRACT Currently,
More informationOriginal article Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV
Antiviral Therapy 2016; 21:605 609 (doi: 10.3851/IMP3066) Original article Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV Edward J Gane 1,2 *, Robert H Hyland 3, Di An 3, Evguenia
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationHepatitis Delta. Vicente Soriano Infectious Diseases Unit La Paz University Hospital & IdiPAZ Madrid, Spain
Hepatitis Delta Vicente Soriano Infectious Diseases Unit La Paz University Hospital & IdiPAZ Madrid, Spain Disclosures Member of speaker bureau and advisory board for: Roche, Boehringer, Gilead, Viiv,
More informationAntiviral therapy guidelines for the general population
Discussion 10 Chapter 10 Hepatitis C a worldwide problem More than 170 million people worldwide suffer from chronic hepatitis C. Its prevalence is 2% in industrialized countries. 1 Approximately 20% of
More informationPersonalizzazione della Cura in Epatologia. Epatite Cronica C: Pazienti con Genotipo 2
Monotematica AISF 213 Personalizzazione della Cura in Epatologia Pisa, 17-19 Ottobre 213 Epatite Cronica C: Pazienti con Genotipo 2 Maria Grazia Rumi U.O. Epatologia, Ospedale San Giuseppe Università degli
More informationOver the past decade, the introduction of
MANAGEMENT OF CHRONIC HEPATITIS C IN HIV-INFECTED PATIENTS: CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α PLUS RIBAVIRIN Raymond T. Chung, MD* ABSTRACT Coinfection with hepatitis C virus (HCV) is common
More informationCurrent therapy for hepatitis C: pegylated interferon and ribavirin
Clin Liver Dis 7 (2003) 149 161 Current therapy for hepatitis C: pegylated interferon and ribavirin John G. McHutchison, MD a, Michael W. Fried, MD b, * a Duke Clinical Research Institute, Duke University
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationChronic hepatitis B affects more than 350 million
GASTROENTEROLOGY 2012;142:513 520 Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B MILAN J. SONNEVELD,* VINCENT W. S. WONG, ANDREA M.
More informationCaution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy Anjana A. Pillai, Emory University Frank A Anania, Emory University Brian L. Pearlman, Emory University
More informationGlecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More informationInfluence of Baseline HCV Genotype upon Treatment Outcome of Acute HCV Infection in HIV Co-Infected Individuals
Influence of Baseline HCV Genotype upon Treatment Outcome of Acute HCV Infection in HIV Co-Infected Individuals Christoph Boesecke, Hans-Jürgen Stellbrink, Stefan Mauss, Emma Page, Mark Nelson, Sanjay
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More information